[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Rugamba et al., 2021 - Google Patents

Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells

Rugamba et al., 2021

View HTML
Document ID
6941796863836668576
Author
Rugamba A
Kang D
Sp N
Jo E
Lee J
Bae S
Jang K
Publication year
Publication venue
Cells

External Links

Snippet

Recently, natural compounds have been used globally for cancer treatment studies. Silibinin is a natural compound extracted from Silybum marianum (milk thistle), which has been suggested as an anticancer drug through various studies. Studies on its activity in various …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Rugamba et al. Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells
Wu et al. Quercetin inhibits the proliferation of glycolysis-addicted HCC cells by reducing hexokinase 2 and Akt-mTOR pathway
Li et al. Myricetin suppresses the propagation of hepatocellular carcinoma via down-regulating expression of YAP
Kang et al. Antitumor effects of ursolic acid through mediating the inhibition of STAT3/PD-L1 signaling in non-small cell lung cancer cells
Sp et al. Potential antitumor effects of 6-gingerol in p53-dependent mitochondrial apoptosis and inhibition of tumor sphere formation in breast cancer cells
Yang et al. Overexpression of X-Box binding protein 1 (XBP1) correlates to poor prognosis and up-regulation of PI3K/mTOR in human osteosarcoma
Ding et al. USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition
Kim et al. Cinobufagin suppresses melanoma cell growth by inhibiting LEF1
Min et al. Potent anticancer effect of the natural steroidal saponin gracillin is produced by inhibiting glycolysis and oxidative phosphorylation-mediated bioenergetics
Chang et al. Endoplasmic reticulum stress contributes to gefitinib-induced apoptosis in glioma
Seo et al. Toxoplasma gra16 inhibits nf-κb activation through pp2a-b55 upregulation in non-small-cell lung carcinoma cells
Su et al. Anti-tumor and radiosensitization effects of N-butylidenephthalide on human breast cancer cells
Huang et al. Inhibition of alternative cancer cell metabolism of EGFR mutated non-small cell lung cancer serves as a potential therapeutic strategy
Wińska et al. Synergistic interactions of 5-fluorouracil with inhibitors of protein kinase CK2 correlate with p38 MAPK activation and FAK inhibition in the triple-negative breast cancer cell line
Kang et al. Metformin and niclosamide synergistically suppress Wnt and YAP in APC-mutated colorectal cancer
Ahn et al. Astaxanthin reduces stemness markers in BT20 and T47D breast cancer stem cells by inhibiting expression of pontin and mutant p53
Lim et al. Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of Forkhead Box M1
Kim et al. Development of oxadiazole-based ODZ10117 as a small-molecule inhibitor of STAT3 for targeted cancer therapy
Kim et al. Dual specificity kinase DYRK3 promotes aggressiveness of glioblastoma by altering mitochondrial morphology and function
Sun et al. Corosolic acid attenuates the invasiveness of glioblastoma cells by promoting CHIP-mediated AXL degradation and inhibiting GAS6/AXL/JAK Axis
Fan et al. Antitumor activity of DFX117 by dual inhibition of c-met and PI3Kα in non-small cell lung cancer
Woo et al. Hispidulin enhances TRAIL-mediated apoptosis via CaMKKβ/AMPK/USP51 axis-mediated bim stabilization
Fontana et al. Exploiting the metabolic consequences of PTEN loss and akt/hexokinase 2 hyperactivation in prostate cancer: a new role for δ-tocotrienol
Hsieh et al. Tesc promotes tgf-α/egfr-foxm1-mediated tumor progression in cholangiocarcinoma
Yoo et al. Regulation of butyrate-induced resistance through AMPK signaling pathway in human colon cancer cells